武田一季度收入按固定汇率下滑且押注三款新药上市

U.S. launches fresh strikes on Iran as fighting intensifies across Middle East
Introduction & Market Context
Takeda Pharmaceutical (NYSE:TAK, TSE:4502) presented its fiscal 2026 first quarter results on July 30, 2026, revealing a company in transition as it prepares to launch three potentially transformative medicines while managing near-term revenue headwinds. The presentation, titled "From Transformation to Growth Acceleration," outlined a strategic framework centered on upcoming product launches that management believes will establish new growth drivers.
The company reported core revenue of JPY 1,219.9 billion ($7.5 billion), which declined 0.5% at constant exchange rates despite growing 10.2% on an actual basis due to favorable foreign exchange movements. Core earnings per share came in at JPY 154 ($0.95), down 11.8% at constant currency. The stock fell 2.2% in premarket trading to $17.36, reflecting investor caution about the underlying performance trends and the execution risk associated with the upcoming launches.
Quarterly Performance Highlights
Takeda’s first quarter results demonstrated the tension between mature portfolio pressures and emerging growth opportunities. As shown in the following comprehensive financial summary, the company delivered results largely in line with expectations while navigating loss of exclusivity challenges and transformation investments.
The revenue decline at constant currency reflected ongoing headwinds from loss of exclusivity products and mature portfolio contraction. However, this was partially offset by growth in core in-line brands, which represented 58% of total revenue and grew 2.3% at constant currency, and new launches, which accounted for 4% of revenue and expanded 22.6% at constant currency.
The detailed financial breakdown reveals the impact of foreign exchange on reported results. As illustrated in the following table, core operating profit of JPY 358.9 billion declined 0.5% at constant exchange rates but grew 11.5% on an actual basis.
Core operating profit margin expanded slightly to 29.4% from 29.1% in the prior year, reflecting the company’s cost discipline efforts. However, reported net profit declined 8.9% to JPY 113.2 billion, while core net profit grew 2.5% on an actual basis but fell 10.9% at constant currency, partly due to favorable tax positioning in the prior year.
Revenue Drivers and Portfolio Dynamics
The composition of Takeda’s revenue growth illustrated the company’s strategic pivot point. The following waterfall chart breaks down the key drivers of year-over-year revenue change.
Core in-line brands contributed positively to revenue, with ENTYVIO remaining a key pillar. The GI franchise leader generated JPY 268.3 billion in revenue, growing 3.8% at constant currency despite competitive pressures. Management highlighted that ENTYVIO maintained its position as the number one prescribed brand in inflammatory bowel disease in the United States, with strong adoption of the pen formulation and double-digit volume growth in international markets driven by subcutaneous penetration.
New launches showed strong momentum, with the portfolio growing 22.6% at constant currency. FRUZAQLA (fruquintinib) led this segment with JPY 17.1 billion in revenue, up 26.8% at constant currency, as the colorectal cancer treatment gained traction in 41 countries. LIVTENCITY (maribavir) generated JPY 14.1 billion, growing 20.8% at constant currency on strong U.S. performance.
Loss of exclusivity products continued to weigh on results, particularly VYVANSE, which saw U.S. revenue decline 60.7% at constant currency to JPY 14.2 billion due to generic competition. The company noted that outside the United States, VYVANSE/ELVANSE grew at double-digit rates with no major loss of exclusivity anticipated in fiscal 2026.
Operating Profit Evolution and Transformation Impact
Takeda’s operating profit development reflected the company’s transformation program investments balanced against cost savings. The following analysis shows how various factors contributed to the year-over-year change in core operating profit.
The transformation program delivered operating expense savings that helped fund growth investments, particularly in the three upcoming launches. New launch investments, primarily for ORZEYFUL, rusfertide, and zasocitinib, represented a significant drag on operating profit, as did increased R&D spending to support late-stage programs TAK-928 and TAK-921.
Reported operating profit showed a different pattern, as illustrated in the next chart, benefiting from the completion of VYVANSE’s amortization period in January 2026.
The company recorded JPY 45.7 billion in restructuring expenses related to the transformation program during the quarter, which partially offset the benefit from reduced amortization. Management indicated that the enterprise transformation was largely implemented by the end of the quarter, with financial savings expected to build gradually through the year.
Strategic Launch Pipeline: Three Transformative Medicines
Takeda’s near-term growth strategy centers on three product launches that management believes will redefine the company’s trajectory. The following overview details these key assets and their expected launch timelines.
ORZEYFUL (oveporexton) represents Takeda’s lead asset, positioned as the first and only orexin agonist for narcolepsy type 1. The drug received approval in China during the quarter and has regulatory submissions under review in the United States and Japan, with a U.S. PDUFA target date in August 2026. Management expects U.S. and Japan launches in the second half of fiscal 2026.
The drug’s clinical profile supports its transformative potential. As shown in the following diagram, ORZEYFUL demonstrated efficacy across a broad range of NT1 symptoms, including excessive daytime sleepiness, cataplexy, nighttime symptoms, functioning, cognition, and quality of life.
Phase 3 data presented at SLEEP 2026 showed significant improvements in daily function, cognition, and nighttime sleep. The drug achieved statistical superiority across all primary and key secondary endpoints with a generally well-tolerated safety profile. Particularly striking was ORZEYFUL’s impact on REM sleep latency, as illustrated in the following clinical data.
The drug shifted mean REM latency into the normative range for all treatment groups, a result Chief Scientific Officer Andy Plump described as "unprecedented." Additionally, ORZEYFUL reduced REM-linked symptoms including hallucinations and sleep paralysis, with reductions mediated by changes in REM features.
Rusfertide, a hepcidin mimetic for polycythemia vera, represents the second major launch. The drug has been filed with the U.S. FDA and is expected to launch in the second half of fiscal 2026 following approval. Management positioned rusfertide as addressing a major unmet need by delivering rapid, stable, and durable hematocrit control while reducing dependence on phlebotomy.
Zasocitinib, a next-generation TYK2 inhibitor for psoriasis, is expected to launch in the first half of fiscal 2027 following NDA submission in fiscal 2026. The drug demonstrated compelling efficacy in Phase 3 studies, as shown in the following head-to-head comparison.
More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16, representing a 2.5-times higher response rate compared to deucravacitinib. The drug showed statistical superiority over deucravacitinib for all primary and key secondary endpoints with a consistent safety profile.
Particularly noteworthy was zasocitinib’s performance in hard-to-treat and high-impact sites, as illustrated in the following efficacy data.
In scalp psoriasis, 77% and 74% of patients achieved clear or almost clear skin in the two Phase 3 studies, compared to 42% and 30% for apremilast. For palms and soles, zasocitinib achieved 71% and 69% clearance rates versus 44% and 43% for apremilast. Plump characterized this as "the best 16-week efficacy in psoriasis that we have seen from a pill."
Broader Pipeline Progress
Beyond the three near-term launches, Takeda advanced multiple late-stage programs across therapeutic areas. The following roadmap illustrates key milestones for gastroenterology, inflammation, and neuroscience assets.
Zasocitinib’s development extends beyond psoriasis, with Phase 2b readouts expected in fiscal 2026 for Crohn’s disease and ulcerative colitis, positioning the asset as a potential franchise. TAK-360, an orexin program for narcolepsy type 2 and idiopathic hypersomnia, initiated Phase 2a studies during the quarter with readouts expected in fiscal 2027.
In oncology and plasma-derived therapies, the pipeline showed similar breadth, as detailed in the following timeline.
TAK-928/IBI363, a bispecific antibody-drug conjugate, presented proof-of-concept data at ASCO for both first- and second-line non-small cell lung cancer. Elritercept initiated Phase 3 studies for first-line anemia-associated myelodysplastic syndromes during the quarter. TAK-881, a subcutaneous immunoglobulin, completed Phase 3 readouts for primary immunodeficiency.
Two Growth Horizons Strategic Framework
Takeda articulated a long-term strategic framework organized around two distinct growth horizons. The following diagram outlines the company’s phased approach to transformation and acceleration.
Horizon One, the current phase, focuses on transforming for growth by establishing new growth drivers through successful launches, advancing the late-stage pipeline, ensuring resilience of core in-line brands, and executing the transformation program to unlock capabilities and efficiencies. Financially, Horizon One targets a return to revenue growth, protection of core operating profit through focused trade-off decisions, improvement in reported profits with return on equity above 5%, and maintenance of strong adjusted free cash flow to drive deleveraging.
Horizon Two envisions growth acceleration by driving scale and maximizing revenue from the first wave of launches, launching the next wave of products from the late-stage pipeline, delivering a steady stream of new drug candidates from the R&D engine, and improving speed, quality, and efficiencies with advanced technology. Financial goals for Horizon Two include compelling revenue growth, core operating profit margin expansion to the low-to-mid 30s percentage range, significant improvement in capital efficiency metrics, and pursuit of targeted investments to fuel further growth.
Full-Year Outlook and Financial Discipline
Takeda maintained its full-year fiscal 2026 guidance unchanged, as detailed in the following forecast table.
The company projects revenue of JPY 4,640.0 billion, representing 3.0% growth on an actual basis but a low-single-digit percentage decline at constant currency. Core operating profit is expected to reach JPY 1,160.0 billion, down 1.1% on an actual basis and declining 5% to 8% at constant currency. Core EPS is forecast at JPY 472, down 8.7% on an actual basis and declining by a mid-teens percentage at constant currency.
Management explained that the revenue guidance reflects mature portfolio headwinds in a year when the company pivots to new launches. Core operating profit assumes substantial investments in new product launches and R&D, partially offset by transformation savings. The core EPS outlook is impacted by a favorable tax position in fiscal 2025 that creates a difficult comparison.
Adjusted free cash flow is projected at JPY 650 billion to JPY 750 billion, reflecting stable cash generation. The company plans to increase its annual dividend to JPY 204 per share, marking 36 consecutive years of dividend payments.
Cash flow performance in the quarter was weaker than the prior year, with operating cash flow declining 40.8% to JPY 127.6 billion and adjusted free cash flow falling 63.9% to JPY 68.6 billion. Management attributed this to working capital changes, particularly related to receivables factoring timing.
Portfolio Brand Performance
Across Takeda’s therapeutic franchises, performance varied by product maturity and competitive dynamics. In gastroenterology, ENTYVIO’s growth was supported by the pen formulation, which saw double-digit sequential patient growth in the United States with an 85% IV to 15% pen volume ratio. The company filed pediatric indications for ulcerative colitis and Crohn’s disease in the United States, Europe, and Japan during June and July 2026.
The rare diseases portfolio faced headwinds as TAKHZYRO reached maturity in an increasingly competitive U.S. market for hereditary angioedema prophylaxis, with revenue declining 2.2% at constant currency to JPY 59.9 billion. However, newer rare disease assets showed strong momentum, with ADZYNMA growing 52.2% at constant currency to JPY 4.1 billion on strong HCP interest for the ultra-rare congenital thrombotic thrombocytopenic purpura population.
In oncology, ADCETRIS grew 14.4% at constant currency to JPY 48.5 billion, driven by increased use in first-line Hodgkin lymphoma following approvals in Europe and 30 other markets for combination therapy. FRUZAQLA’s 26.8% constant currency growth reflected expansion to 41 countries and strong demand for novel non-chemotherapy options in metastatic colorectal cancer.
The neuroscience portfolio reflected the VYVANSE loss of exclusivity impact, with overall franchise revenue declining 5% at constant currency. TRINTELLIX partially offset this with 21.2% constant currency growth to JPY 37.0 billion, though management noted that generic launches are expected in the United States from December 2026.
Plasma-derived therapies showed mixed results, with immunoglobulin revenue declining 0.6% at constant currency to JPY 213.9 billion, impacted by IVIG phasing in the United States. The SCIG portfolio grew 17% at constant currency, supporting the company’s margin improvement strategy. Management expects full-year immunoglobulin growth in the mid-single-digit percentage range at constant currency.
Analyst and Investor Considerations
The presentation and subsequent market reaction highlighted several key considerations for investors. The company’s ability to execute on three simultaneous launches in the coming months represents significant operational risk, particularly as each product targets different therapeutic areas and commercial channels.
Launch pricing and reimbursement dynamics remain uncertain. For ORZEYFUL, management indicated positioning as a monotherapy for diagnosed NT1 patients with pricing aimed at balancing value and access, though final pricing details were not disclosed. Rusfertide pricing is expected to reflect the drug’s value proposition in reducing phlebotomy dependence, with details forthcoming.
The constant currency revenue and earnings pressure in fiscal 2026 creates a challenging backdrop for the launches, requiring significant commercial execution to offset mature portfolio declines. The company’s transformation program savings are expected to build gradually, meaning near-term margin pressure may persist.
Competition in key franchises also bears watching. ENTYVIO faces potential biosimilar competition, with management acknowledging awareness of vedolizumab biosimilar marketing authorization applications and stating preparedness to defend patents. In psoriasis, zasocitinib enters a crowded market despite strong efficacy data, requiring differentiation on both clinical and commercial dimensions.
The company’s financial discipline framework through the two growth horizons provides strategic clarity, though achieving the Horizon Two targets of low-to-mid 30s percentage core operating profit margins and compelling revenue growth depends heavily on launch execution and pipeline advancement.
Analyst price targets ranging from $19.02 to $22.84 suggest potential upside from current levels, though the 2.2% premarket decline indicates near-term caution about the company’s ability to bridge from its transformation phase to sustained growth acceleration.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.